|
1
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu S, Zhang GM, Guan FJ, Dong DH, Luo L,
Li B, Ma XC, Zhao J and Sun LJ: The association between metabolic
syndrome and the risk of urothelial carcinoma of the bladder: A
case-control study in China. World J Surg Oncol. 13:2362015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rocken C and Behrens HM: Validating the
prognostic and discriminating value of the TNM-classification for
gastric cancer - a critical appraisal. Eur J Cancer. 51:577–586.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eble JN, Sauter G, Epstein JI and
Sesterhen IA: World Health Organization Classification of Tumours.
Pathology and genetics of tumours of the urinary system and male
genital organs. IARC Press. (Lyon). 2004.
|
|
6
|
Soloway MS: Bladder cancer: Lack of
progress in bladder cancer - what are the obstacles? Nat Rev Urol.
10:5–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chamie K and Litwin MS: Quality of bladder
cancer care in the USA. Expert Rev Pharmacoecon Outcomes Res.
11:619–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corcoran AT, Handorf E, Canter D,
Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A and
Smaldone MC: Variation in performance of candidate surgical quality
measures for muscle-invasive bladder cancer by hospital type. BJU
Int. 115:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jayaratna IS, Navai N and Dinney CP: Risk
based neoadjuvant chemotherapy in muscle invasive bladder cancer.
Transl Androl Urol. 4:273–282. 2015.PubMed/NCBI
|
|
10
|
Johnson DC, Greene PS and Nielsen ME:
Surgical advances in bladder cancer: At what cost? Urol Clin North
Am. 42:235–252, ix. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beitzinger M and Meister G: Preview.
MicroRNAs: From decay to decoy. Cell. 140:612–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maida Y, Takakura M, Nishiuchi T,
Yoshimoto T and Kyo S: Exosomal transfer of functional small RNAs
mediates cancer-stroma communication in human endometrium. Cancer
Med. 5:304–314. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim MS, Haney MJ, Zhao Y, Mahajan V,
Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O,
et al: Development of exosome-encapsulated paclitaxel to overcome
MDR in cancer cells. Nanomedicine. 12:655–664. 2016.PubMed/NCBI
|
|
17
|
Catto JW, Miah S, Owen HC, Bryant H, Myers
K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, et al:
Distinct microRNA alterations characterize high- and low-grade
bladder cancer. Cancer Res. 69:8472–8481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B,
Amsellem-Ouazana D, et al: MicroRNA expression profile in a large
series of bladder tumors: Identification of a 3-miRNA signature
associated with aggressiveness of muscle-invasive bladder cancer.
Int J Cancer. 132:2479–2491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Segersten U, Spector Y, Goren Y, Tabak S
and Malmström PU: The role of microRNA profiling in prognosticating
progression in Ta and T1 urinary bladder cancer. Urol Oncol.
32:613–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Whiting PF, Rutjes AW, Westwood ME,
Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt
PM: QUADAS-2 Group: QUADAS-2: A revised tool for the quality
assessment of diagnostic accuracy studies. Ann Intern Med.
155:529–536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dinnes J, Deeks J, Kirby J and Roderick P:
A methodological review of how heterogeneity has been examined in
systematic reviews of diagnostic test accuracy. Health Technol
Assess. 9:1–113, iii. 2005. View
Article : Google Scholar
|
|
22
|
Veerla S, Lindgren D, Kvist A, Frigyesi A,
Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, et
al: miRNA expression in urothelial carcinomas: Important roles of
miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and
metastasis, and frequent homozygous losses of miR-31. Int J Cancer.
124:2236–2242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana
D and Bieche I: MicroRNA expression profile in a large series of
bladder tumors: Identification of a 3-miRNA signature predictive of
aggressiveness and prognosis of muscle-invasive bladder cancer. Eur
Urol Suppl. 11:e1692012. View Article : Google Scholar
|
|
24
|
Pignot G, Vieillefond A, Vacher S, Zerbib
M, Debre B, Lidereau R, Amsellem-Ouazana D and Bieche I: Hedgehog
pathway activation in human transitional cell carcinoma of the
bladder. Br J Cancer. 106:1177–1186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adam L, Wszolek MF, Liu CG, Jing W, Diao
L, Zien A, Zhang JD, Jackson D and Dinney CP: Plasma microRNA
profiles for bladder cancer detection. Urol Oncol. 31:1701–1708.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ratert N, Meyer HA, Jung M, Lioudmer P,
Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert
S, et al: miRNA profiling identifies candidate mirnas for bladder
cancer diagnosis and clinical outcome. J Mol Diagn. 15:695–705.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li H, Yu G, Shi R, Lang B, Chen X, Xia D,
Xiao H, Guo X, Guan W, Ye Z, et al: Cisplatin-induced epigenetic
activation of miR-34a sensitizes bladder cancer cells to
chemotherapy. Mol Cancer. 13:82014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Avgeris M, Mavridis K, Tokas T,
Stravodimos K, Fragoulis EG and Scorilas A: Uncovering the clinical
utility of miR-143, miR-145 and miR-224 for predicting the survival
of bladder cancer patients following treatment. Carcinogenesis.
36:528–537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Zhang X, Wang L, Dong Z, Du L,
Yang Y, Guo Y and Wang C: Downregulation of urinary cell-free
microRNA-214 as a diagnostic and prognostic biomarker in bladder
cancer. J Surg Oncol. 111:992–999. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao
YC, Xu LW, Yang XB, Geng LG, Dou QL, et al: MicroRNA expression
profiles in muscle-invasive bladder cancer: Identification of a
four-microRNA signature associated with patient survival. Tumour
Biol. 36:8159–8166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang Z, Dai W, Wang X, Chen W, Shen C, Ye
G and Li L: Circulating miR-205: A promising biomarker for the
detection and prognosis evaluation of bladder cancer. Tumour Biol.
37:8075–8082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Catto JW, Abbod MF, Wild PJ, Linkens DA,
Pilarsky C, Rehman I, Rosario DJ, Denzinger S, Burger M, Stoehr R,
et al: The application of artificial intelligence to microarray
data: Identification of a novel gene signature to identify bladder
cancer progression. Eur Urol. 57:398–406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Silva-Santos RM, Costa-Pinheiro P, Luis A,
Antunes L, Lobo F, Oliveira J, Henrique R and Jerónimo C: MicroRNA
profile: A promising ancillary tool for accurate renal cell tumour
diagnosis. Br J Cancer. 109:2646–2653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang X, Du L, Wang L, Li J, Liu Y, Zheng
G, Qu A, Zhang X, Pan H, Yang Y, et al: Serum microRNA expression
signatures identified from genome-wide microRNA profiling serve as
novel noninvasive biomarkers for diagnosis and recurrence of
bladder cancer. Int J Cancer. 136:854–862. 2015. View Article : Google Scholar : PubMed/NCBI
|
